A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C

Major Inclusion Criteria: * Have a clinical diagnosis of chronic HEP C established on the basis of detectable viral load, as measured by a serum HCV RNA test during the screening period. * Have previously failed to respond to treatment with any interferon alfa (IFNa) product * Have compensated liver disease with the following minimum criteria: white blood cell count \> 3,000/mm3, absolute neutrophil count (ANC) \> 2,000/mm3, platelets \> 125,000/mm3, and hemoglobin (Hb) \> 13 g/dL for males or \> 12 g/dL for females. Major Exclusion Criteria: * Evidence of decompensated cirrhosis or portal hypertension. * Pregnant or lactating female. * History of any other medical disease or condition that would make the subject (in the opinion of the investigator) unsuitable for the study. * A current drug or alcohol addiction